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Fluorescence lifetime imaging of receptor tyrosine kinase activity
in cells
Fred S. Wouters and Philippe I.H. Bastiaens
We report a highly specific fluorescence lifetime imaging
microscopy (FLIM) method for monitoring epidermal
growth factor receptor (EGFR) phosphorylation in cells
based on fluorescence resonance energy transfer (FRET).
EGFR phosphorylation was monitored using a green
fluorescent protein (GFP)-tagged EGFR and
Cy3-conjugated anti-phosphotyrosine antibodies. In this
FRET-based imaging method, the information about
phosphorylation is contained only in the (donor) GFP
fluorescence lifetime and is independent of the antibody-
derived (acceptor) fluorescence signal. A pixel-by-pixel
reference lifetime of the donor GFP in the absence of
FRET was acquired from the same cell after
photobleaching of the acceptor. We show that this
calibration, by acceptor photobleaching, works for the
GFP–Cy3 donor–acceptor pair and allows the full
quantitation of FRET efficiencies, and therefore the
degree of exposed phosphotyrosines, at each pixel. The
hallmark of EGFR stimulation is receptor dimerisation
[1–4] and concomitant activation of its intracellular
tyrosine kinase domain [5–7]. Trans-autophosphorylation
of the receptor [8,9] on specific tyrosine residues couples
the activated dimer to the intracellular signal
transduction machinery as these phosphorylated
residues serve as docking sites for adaptor and effector
molecules containing Src homology 2 (SH2; reviewed in
[10]) and phosphotyrosine-binding (PTB) [11] domains.
The time-course and extent of EGFR phosphorylation are
therefore important determinants of the underlying
pathway and resulting cellular response. Our results
strongly suggest that secondary proteins are recruited by
activated receptors in endosomes, indicating that these
are active compartments in signal transduction.
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Results and discussion
GFP was fused to the carboxyl terminus of the EGFR
(EGFR–GFP) via a six-glycine linker (see Supplementary
material) to enable monitoring of intracellular binding
events by FRET (Figure 1). The integrity of the expressed
protein was confirmed by western blotting of transfected
Cos-7 cells and immunodetection with anti-GFP antibod-
ies. A single ~200 kDa polypeptide was detected, indicat-
ing that the expressed fusion protein is proteolytically
stable in the cells (data not shown). Receptor function in
response to EGF stimulation was verified by following its
distribution by conventional immunofluorescence. Serum-
starved cells showed a homogeneous plasma-membrane
distribution of EGFR–GFP. Occasionally, EGFR–GFP
accumulated in compartments of the protein synthesis
pathway in cells expressing high levels of the fusion
protein. Stimulation with 100 ng/ml EGF caused aggrega-
tion of the EGFR–GFP associated with the plasma mem-
brane, followed by receptor internalisation at longer
stimulation times. Proper EGF binding was shown by the
colocalisation of Cy3-labeled EGF and EGFR–GFP at the
plasma membrane and, after endocytosis, on endosomes
(data not shown). The presence of a GFP moiety on the
EGFR has previously been shown not to interfere with its
proper functioning in cells [12,13].
Total EGF-dependent phosphorylation of EGFR–GFP
was indicated by immunoprecipitation of the EGFR–GFP
with an anti-GFP antibody and subsequent detection
with an anti-phosphotyrosine antibody. Negligible
phosphorylation was detected before EGF stimulation in
quiescent Cos-7 cells. Upon stimulation with 100 ng/ml
EGF, the EGFR–GFP was rapidly phosphorylated and
this phosphorylation level was sustained throughout the
30 minute stimulation period (Figure 2a). Quiescent
Cos-7 cells were stimulated with EGF, fixed and incu-
bated with Cy3-labeled anti-phosphotyrosine antibodies
(see Supplementary material and [14]). 
Frequency domain FLIM [15–17] was used to map the
fluorescence lifetimes of the GFP moiety of the
EGFR–GFP in cells at different time points during EGF
stimulation. The fluorophores GFP and Cy3 form a
favourable Förster donor–acceptor pair with an R0 value
(defined as the distance at which 50% of the excited donor
molecules transfer energy by FRET) of 6 nm [18]. This
allows for efficient detection of FRET at inter-chro-
mophore distances of up to approximately 9 nm. The fluo-
rescence lifetime of EGFR–GFP decreases because of
FRET to Cy3. As FRET occurs over distances that are in
the same order of magnitude as protein dimensions,
detectable FRET efficiencies can be interpreted as a
direct interaction between phosphorylated EGFR–GFP
and Cy3-labeled anti-phosphotyrosine antibodies. Com-
plete photobleaching of the Cy3 acceptor by continuous
illumination provides a pixel-by-pixel reference GFP donor
fluorescence lifetime for the calculation of FRET efficien-
cies (Figure 1). An alternative readout for EGFR–GFP
phosphorylation is provided by determining FRET from
the recovery of GFP fluorophore (donor) emission intensity
after photobleaching of the acceptor [19]. The latter is per-
formed in a confocal microscopy set-up in which FRET is
determined in a defined region of the cell where the Cy3
acceptor is photobleached by repeated scanning.
The EGFR–GFP showed a plasma membrane distribu-
tion when expressed in quiescent Cos-7 cells, and nascent
protein was located in compartments of the secretory
pathway (Figure 2b). Upon EGF stimulation, EGFR–GFP
translocated from the plasma membrane to punctate struc-
tures that represent vesicles in various stages of endocyto-
sis (Figure 2b,3). In quiescent cells, the corresponding
Cy3-labeled anti-phosphotyrosine antibody distribution
(Figure 2c) was limited to punctate structures and the cell
perimeter, a distribution that corresponds to phosphoryla-
tion sites that are independent of growth factor stimula-
tion, for example, those located at focal adhesions.
Despite colocalisation of the EGFR–GFP at the plasma
membrane and the phosphotyrosines at focal adhesions,
the fluorescence lifetime image showed no FRET at
these sites (Figure 2d, time 0), confirming that the FRET-
based imaging approach only reports on phosphotyrosine
residues on the EGFR–GFP. Upon EGF stimulation, the
anti-phosphotyrosine antibody staining largely colocalised
with the EGFR–GFP distribution, with particularly high
phosphorylation levels in membrane ridges and additional
punctate structures (Figure 2c). Although, as expected,
short lifetimes were generally associated with high levels
of anti-phosphotyrosine staining, there were significant
differences. Structures with high phosphotyrosine content
were seen that exhibited low FRET efficiencies at the
plasma membrane and in punctate structures after 5 and
10 minutes of EGF stimulation (Figure 2d). These sites
must therefore contain phosphorylated proteins other than
the EGFR–GFP, for example, recruited EGFR tyrosine-
kinase substrates. Furthermore, EGFR–GFP in the secre-
tory pathway provided an internal control for the FRET
measurements because it should have been unresponsive
to EGF stimulation. Indeed, this can be seen at all time-
points measured: no energy transfer was detected for the
nascent receptor in the perinuclear region. The presence
of FRET in other structures was confirmed by photo-
bleaching of the Cy3 acceptor, which resulted in a homo-
geneous distribution of GFP fluorescence lifetimes similar
to those seen in the unstimulated situation (Figure 2e,g).
These results show that acceptor photobleaching can
indeed be used to calibrate FRET determinations via
donor lifetime measurements. The reference GFP lifetime
maps obtained after Cy3 acceptor photobleaching enabled
the pixel-by-pixel calculation of FRET efficiency maps
(Figure 2f). An alternative procedure was used to obtain
FRET efficiencies on a confocal microscope by
unquenching GFP donor emission after Cy3 photode-
struction by repeated scanning. In Cos-7 cells expressing
EGFR–GFP, the FRET efficiencies obtained this way
after 5 minutes of EGF stimulation were comparable
(0.2–0.25) to those obtained by FLIM (Figure 3). As can
be seen by comparing Figures 2 and 3, the confocal accep-
tor-photobleaching method yields noisier FRET maps
and furthermore proper image registration is essential.
The FLIM approach is inherently more sensitive and
does not suffer from photobleaching of the donor because
the fluorescence lifetime is an intrinsic property of the flu-
orophore and therefore independent of emission intensity.
The GFP fluorescence lifetimes at later time points during
EGF stimulation (from 20 minutes) revert to the distribu-
tion seen in the absence of FRET (Figure 2d,g). The
phosphotyrosine staining at these time points decreased
compared to earlier time points of stimulation, but still
showed punctate structures. As phosphorylation of the
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Figure 1
Schematic representation of FRET
determination by acceptor photobleaching.
(a) The GFP fluorescence lifetime (τDA) or
emission intensity (FDA) is acquired in the
presence of Cy3-labeled antibodies. (b) The
Cy3 is completely photobleached by
continuous illumination (FLIM) or repeated
scanning (confocal microscopy) with 633 nm
light. (c) The GFP τD or FD is again acquired.
(d) From the measurements in (a,c), FRET
efficiencies (E) can be calculated.
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EGFR–GFP persisted, as judged by immunoprecipitation
(Figure 2a), this loss of FRET can only be accounted for
by the shielding of epitopes by proteins recruited to the
activated receptors in endosomes. These results were also
consistently reproduced in NR6 fibroblasts that are devoid
of endogenous EGFR and in MCF-7 breast carcinoma
cells (data not shown). In all cells tested, the observed
effect was independent of EGFR–GFP expression level.
This pattern of EGF-dependent phosphorylation can also
be seen in the two-dimensional histograms (Figure 2g), in
which the phase lifetime (τφ) and modulation lifetime (τM)
values for each pixel are plotted. Before stimulation, the
distribution of lifetimes after acceptor photobleaching
(red) showed a stable homogeneous distribution that over-
lapped the distribution of lifetimes measured in the pres-
ence of acceptor (green; overlap is yellow). Upon EGF
stimulation for 5 minutes, FRET was seen as a shortening
in both lifetimes, giving rise to a new population with
shorter lifetimes (green). A significant ‘tail’ of pixels with
even shorter lifetimes was present after 10 minutes of
EGF stimulation, indicating the presence of highly phos-
phorylated EGFR–GFP species. At later time points, the
lifetime distributions in the presence and absence of
acceptor converged again, indicating a loss of FRET. A
number of studies have indeed suggested recruitment of
Grb2, Shc, the Grb2–Shc–mSOS complex and Ras–GAP
to the phosphorylated EGFR in endosomes [20].
Furthermore, the molecules involved in the MAP-kinase
signal transduction pathway have been identified in
endosomes [21]. Internalisation is generally viewed as an
attenuation mechanism. The cytosolic orientation of the
EGFR phosphotyrosine residues, however, implies that
the complex of associated signaling molecules can be
brought into close proximity of other cytosolic targets by
receptor endocytosis and thereby provides an attractive
alternative scenario for sustained signal transduction [22].
As can be seen from the differences between the phos-
photyrosine and FRET distributions, conventional co-
localisation studies do not accurately report on
phosphorylated species when other tyrosine-phosphorylated
proteins are also present in the same location. Although the
use of antibodies specific for the phosphorylated EGFR
could alleviate this problem, such antibodies are restricted
to a single phosphotyrosine epitope and for many phospho-
rylated proteins, antibodies are not yet available. Most
importantly, antibody staining does not provide a quantita-
tive measure of the extent of phosphorylation, in contrast
to the FRET determination. Because FRET is measured
on the donor fluorophore independently of the acceptor
fluorescence, non-specific interaction of the anti-phospho-
aminoacid antibody is of no consequence to the measure-
ment. This means that serine phosphorylation could also
be measured by this approach as anti-phosphoserine anti-
bodies are usually not as specific as anti-phosphotyrosine
antibodies. For the same reason, the relative intensities of
the GFP fluorescence and the immunolabeling have no
effect on the measurements, enabling detection of phos-
phorylation in cells with low expression levels of the GFP
protein, even in the presence of extensive immunolabel-
ing. This allows selectivity to be sacrificed in favour of
achieving higher epitope occupancy with higher antibody
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Figure 2
FRET determination of the degree of
phosphorylation of EGFR–GFP by FLIM.
(a) Western blot of anti-phosphotyrosine
immunostaining of anti-GFP
immunoprecipitates from Cos-7 cells
stimulated with EGF for the indicated times.
(b) GFP fluorescence intensity distribution at
different time points during EGF stimulation.
Areas within the cells with saturated
intensities were excluded from the analysis
(black). (c) Cy3–anti-phosphotyrosine
antibody fluorescence intensity distribution in
the same cells as shown in (b). (d,e) Colour-
coded GFP fluorescence lifetime maps
(d) before and (e) after photobleaching of the
acceptor. (f) FRET efficiency maps calculated
by division of the images in (d) by the images
in (e) (see Supplementary material).
Calibration bars below show values for GFP
fluorescence lifetime (<τ>) and FRET
efficiency (E). (g) Two-dimensional histograms
of the fluorescence lifetimes determined from
phase shift (τφ) and demodulation (τM) of the
GFP emission.
(g)(b) (c) (d) (e) (f)
3
3 nsec11
τ M
1 .5 2.5 nsec2.0<τ>
0 5
   Current Biology
10 15 20 30
(a)
0
5
10
30
τφ
–0.1 0.2E 0 0.1
Ti
m
e 
(m
in
)
Time (min)
concentrations. Acceptor photobleaching to abolish FRET
is a simple operation that allows the unequivocal assign-
ment of decreased lifetimes to FRET by providing a pixel-
by-pixel calibration in the same cell, and effectively
reducing inter-sample variation. This type of imaging assay
is generally applicable to other systems, in which a GFP-
tagged protein and antibodies against a binding candidate
are available.
Supplementary material
Supplementary material including additional methodological detail is
available at http://current-biology.com/supmat/supmatin.htm.
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Figure 3
Confocal acceptor-photobleaching FRET
imaging of phosphorylated EGFR–GFP in
Cos-7 cells after 5 min of EGF stimulation.
(a,b) EGFR–GFP fluorescence (a) before and
(b) after photobleaching of the acceptor.
(c,d) Cy3–anti-phosphotyrosine antibody
fluorescence (c) before and (d) after
photobleaching of the region of the cell
marked by a white rectangle. (e) FRET
efficiency map of the cell, calculated by
division of the image in (a) by the image in (b).
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Supplementary materials and methods
EGFR–GFP construction
A unique PvuI restriction site and six glycine residues were introduced
directly upstream of EGFP by ligation of a linker (formed by annealing
GATCGGTGGAGGTGGAGGAGGC and CCTCCTCCACCTCCAC-
CGATCG oligonucleotides) into the unique XcmI site of pEGFP-N3.
The 2927 bp NheI–BglII fragment of human EGFR (Genbank acces-
sion number X00588) was subcloned into the respective sites in the
modified pEGFP-N3. The 3′ part of the EGFR cDNA was obtained by
PCR with primers designed to include the BglII site (GAGTTGATGAC-
CTTTGGATCCAAGCCATA) and to introduce a unique PvuI site
(TGGCTAGCGACGAGGTTATTTAAGTGACGAAACAC). The full-
length construct was obtained by ligation of the 929 bp BglII–PvuI
fragment of the PCR product into the respective sites of the host
vector and was confirmed by sequence analysis.
Immunoprecipitation
Cos-7 cells were transfected with EGFR–GFP by lipofection (Fugene,
Boehringer Mannheim) for 24–36 h and were starved for 12 h. The
Cos-7 cells were stimulated for the indicated times with 100 ng/ml
mouse submaxillary gland EGF (Sigma) and were lysed in modified
RIPA buffer (1% Triton X-100, 0.5% NaDoC, 0.1% SDS, 0.2% NaN3,
0.04% NaF, 2 mM NaVO3 and 1× complete protease inhibitor mix
(Boehringer Mannheim)) for 20 min at 4°C. EGFR–GFP was immuno-
precipitated with 15 µg of anti-GFP monoclonal antibody (3E1) and
protein A sepharose (Biorad). The immunoprecipitate was elec-
trophoresed, transferred to nitrocellulose by western blotting and phos-
photyrosine-containing proteins were detected using 2.5 µg/ml
anti-phosphotyrosine antibody (PY72) by enhanced chemilumines-
cence (ECL; NEN/Dupont).
Fluorescence lifetime imaging microscopy
Cos-7 cells expressing EGFR–GFP were fixed in 4% formalde-
hyde + 1 mM NaVO3 and then permeabilised with 0.1% Triton X-100
in phosphate-buffered saline for 10 min. The cells were incubated with
15 µg/ml Cy3-labeled (Cy3:protein ratio = 8) PY72 antibody and
mounted in 0.1 M Tris–HCl, 25% (wt/vol) glycerol, and 10% (wt/vol)
Mowiol 4-88 (Hoechst).
FLIM was performed on a Zeiss Axiovert 135 TV microscope equipped
with a 100×/NA 1.4 plan-apochromat objective. EGFR–GFP was
excited at 488 nm using a Coherent Innova Argon/Krypton laser modu-
lated at 80.244 MHz. GFP emission was detected using a 505 LP
dichroic mirror (Chroma) and a 514/10 BP emission filter (Delta Lys &
Optik). A series of phase-dependent images was acquired as
described in [S1] and used to determine GFP lifetimes from phase
shift (τφ) and demodulation (τM) on a pixel-to-pixel basis.
Energy transfer efficiency maps were calculated from fluorescence life-
time maps according to: E = 1–(<τ>DA/<τ>D) where <τ>DA is the
average of the lifetimes determined from the phase shift (τφ) and
demodulation (τm) of the donor emission in presence of the acceptor
and <τ>D after photobleaching of the acceptor.
Confocal acceptor-photobleaching FRET imaging
Acceptor-photobleaching imaging was performed on a Zeiss LSM 510
confocal microscope with 488 nm (Argon laser) GFP and 633 nm
(Helium/Neon laser) Cy3 excitation. GFP emission was detected using
a BP 505–530 nm filter and Cy3 using a BP 560–605 nm filter.
In this approach the quenching of donor fluorescence intensity by
FRET was utilised by acquisition of a donor (GFP) image before and
after photobleaching of the acceptor, essentially as described in [S2].
Acceptor photobleaching unquenches GFP fluorescence since FRET
is abolished and enables the determination of the FRET (quenching)
efficiency by: E = 1–(FDA/FD) where FDA is the donor image in presence
of acceptor and FD in the absence of acceptor.
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